Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 11/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274655 | 0.85 | ALOX5 (0.46) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2484255 | 0.80 | ALOX5 (0.48) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2597432 | 0.79 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13933085 | 0.79 | PTGS1 (0.79) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4188114 | 0.78 | CYP3A4 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL4647438 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| (R)-Trolox SCHEMBL615168 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1927837 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL3226 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1651402 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584728-B2 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210206736-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. | 2021-07-08 | — | — | US | disclosed |
| WO-2019053605-A1 | SYNTHESIS OF TOCOTRIENOLS FROM O-CRESOL DERIVATIVES | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2019-03-21 | — | — | WO | disclosed |
| US-7615650-B2 | Process for producing chroman compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20070179304-A1 | Process for producing chroman compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1710239-A1 | PROCESS FOR PRODUCING CHROMAN COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584728-B2 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | FH, COQ8A, TFAM | PTGS1 682/4885PTGS2 1030/4885CYP1A2 2185/4885 |
| US-20210206736-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | FH, COQ8A, TFAM | PTGS1 682/4885PTGS2 1030/4885CYP1A2 2185/4885 |
| US-20070179304-A1 | Process for producing chroman compound | TAF9, TAF1, CHD1 | PTGS1 509/4885PTGS2 1158/4885CYP1A2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.